World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

James Kilts Biography and Net Worth

Director of Viatris

James Kilts joined the Viatris board of directors after 13 years of service on the Pfizer board, where he was most recently a member of the Compensation Committee. Kilts also serves as a director of The Simply Good Foods Company and Unifi, Inc. He served as executive chairman of the board of Conyers Park II Acquisition Corp., a special purpose acquisition company and an affiliate of Centerview Capital, from 2016 until its merger with The Simply Good Foods Company in 2017. Kilts is a founding partner of Centerview Capital, a private equity firm. He previously served as vice chairman of The Proctor and Gamble Company, chairman and chief executive officer of The Gillette Company, president and chief executive officer of Nabisco Group Holdings Corp., chairman of the Nielsen Company B.V., chairman of Big Heart Pet Brands, and a director of MeadWestvaco Corporation.

What is James M. Kilts' net worth?: The estimated net worth of James M. Kilts is at least $7.41 million as of November 9th, 2023. Mr. Kilts owns 641,417 shares of Viatris stock worth more than $7,408,366 as of April 24th. This net worth approximation does not reflect any other assets that Mr. Kilts may own. Learn More about James M. Kilts' net worth.
How do I contact James M. Kilts?: The corporate mailing address for Mr. Kilts and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on James M. Kilts' contact information.
Has James M. Kilts been buying or selling shares of Viatris?: James M. Kilts has not been actively trading shares of Viatris within the last three months. Most recently, on Wednesday, December 16th, James M. Kilts bought 27,736 shares of Viatris stock. The stock was acquired at an average cost of $17.66 per share, with a total value of $489,817.76. Following the completion of the transaction, the director now directly owns 64,905 shares of the company's stock, valued at $1,146,222.30. Learn More on James M. Kilts' trading history.
Who are Viatris' active insiders?: Viatris' insider roster includes W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.
Are insiders buying or selling shares of Viatris?: During the last twelve months, insiders at the sold shares 8 times. They sold a total of 325,290 shares worth more than $3,901,932.18. The most recent insider tranaction occured on March, 13th when insider Anthony Mauro sold 250,000 shares worth more than $3,022,500.00. Insiders at Viatris own 0.3% of the company. Learn More about insider trades at Viatris.
Information on this page was last updated on 3/13/2024.

James M. Kilts Insider Trading History at Viatris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/16/2020	Buy	27,736	$17.66	$489,817.76	64,905

James M. Kilts Buying and Selling Activity at Viatris

Viatris Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Today's Range

Now: $11.41

$11.36

$11.65

50 Day Range

MA: $12.07

$11.10

$13.53

2 Week Range

Now: $11.41

$8.74

$13.62

Volume

1,790,457 shs

Average Volume

9,248,232 shs

Market Capitalization

$13.69 billion

P/E Ratio

285.25

Dividend Yield

4.23%

Beta

1.13

Mysterious Gold Leverage Just Announced

From Stansberry Research | Ad